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Abstract 
Breast cancer is the most frequent carcinoma in females. The present study aimed to shed light on the association 
between the breast cancer incidence and BRAC1 gene mutations. This study was carried out on two groups of 
30breast cancer patients and 10 of healthy control. Polymerase chain reaction (PCR) for exon 2 of BRCA1 was 
performed to detect the gene mutations.The results showed 21(70%) samples were negative to BRCA1gene 
mutation while 9 (30%) samples were positive to it, which was a significant difference (p value=0.0984 <0.05). 
The statistical analysis showed no significant differences in the frequency of BRCA1 gene mutation with age and 
family history. In correlation with the tumor stage, the highest percentage of BRCA1gene mutation positive 
samples 7(77.77%) were stage II that statistically no significant differences from percentage of stage III.In 
conclusion, the BRCA1 gene mutation may play a key role in breast cancer incidence and have a relatively high 
frequency in tumor stage II . 
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1- Introduction 
Breast cancer is the most frequent carcinoma in females and the second most common cause of cancer related 
mortality in women (Bombonati and Dennis , 2011) . It is the most commonly diagnosed malignancy in women 
around the world, especially in the Western countries. It accounts for almost one fifth of deaths caused by cancer 
(Winer et al., 2001). Every year, one million new cases are reported worldwide, representing 18% of the total 
number of cancer in women. It has been established that one out of eight women (in USA) and one out of 10 
women (in UK) (Evans and Lalloo , 2002) will develop breast cancer at some point in her life. An Iraqi studies 
shown that the number of breast cancer cases are steadily rising since the 1991 war (Berchuck , 1999 ; Jasim , 
2004). The genetic contribution to breast cancer risk is indicated by the increased incidence of breast cancer 
among women with a family history of the disease and by the observation of families in which multiple members 
have breast cancer in a pattern compatible with autosomal dominant inheritance of cancer susceptibility. Linkage 
analysis studies of families have led to the identification of highly penetrant genes as the possible cause of 
inherited cancer risk in many cancer-prone families (Hall et al., 1990). However, mutations in these genes are 
rare, and account for no more than 5–10% of breast cancer cases. It is probably that other background genetic 
factors contribute to the etiology of breast malignancies, Hopper(2001). Autosomal dominant inherited 
predisposition to breast cancer is characterized by early age at onset, bilaterally, vertical transmission through 
both maternal and paternal lines, and familial association with tumors of other organs. Identification of the 
BRCA1 and BRCA2 genes marked an important step in understanding the molecular bases of the hereditary 
susceptibility to cancer (Wooster et al.,1995).  BRCA1gene appears to be responsible for disease in 45% of 
families with multiple cases of breast cancer only and up to 90% of families with both breast and ovarian cancer. 
BRCA1 is mapped to chromosome 17q21 (Hall et al., 1990) ; it contains 24 exons and encodes a protein of 220 
KDa, composed of 1863 amino acids. BRCA1 contains only two recognizable protein motifs, a RING finger 
domain near the N-terminus and a BRCT domain at the C-terminus. The phenotype for BRCA-related tumors 
appears to be heterogeneous, and to date is better characterized in BRCA1 than in BRCA2 (Phillips,2000). 
Different types of mutation have been found in the BRCA1 gene and predispose to development of cancer. The 
most common of them is the frame shift mutation at position 185 in exon 2, involving deletion of adenine and 
guanine (185 del AG mutation) (Bonatti et al., 2006). The identification and study of this mutation could 
facilitate early diagnosis and proper counseling for breast cancer. In this study, we analyzed the frequency of the 
185 del AG mutation (exon 2) of BRCA1 gene BRCA1 gene mutation in 30 breast cancer samples using 
conventional polymerase chain reaction and estimate the hypothesis that  there is an association between risk for 
developing breast cancer and BRCA1 gene mutation. 
 
2-Materials and Methods 
Patients and clinical samples: the blood samples from 30 patients with different stages of newly diagnosed breast 
cancer were provided by Tumor center/ Alsader Hospital /Missan during the period from December 2015 to 
March 2016. 20 blood samples from healthy donors were used as a control in this study. From each sample, 2 
mL of peripheral blood was collected into an EDTA-containing tube. The samples were stored at -20Cº until 
further processing. 
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2-1 DNA extraction and Polymerase chain reaction 
DNA was extracted from frozen blood samples by the gSYNCDNA Mini method (Geneaid/ Taiwan) according 
to the “frozen blood protocol”. 
Polymerase chain reaction (PCR) of exon 2BRCA1was performed using an ABI thermal cycler (Applied 
Biosystems / Korea). The primer sequences used are shown in Table 1, (Alpha DNA/Canada). PCR 
amplification was performed in a total volume of 25 µl containing, 5 µl dNTPs, 1 µl of each primer, master mix 
(Promega/USA),12.5 µl, and nuclease free water 5.5 µl. The following program was used : 1 cycle at 95°C for 5 
minutes followed by 33 cycles at 94°C for 1 minute, 58°C for 1 minute and 72°C for 1 minute, 1 cycle at 72°C 
for 10 minutes. The PCR amplification products were separated by2% agarose gel electrophoresis and visualized 
by exposure to ultraviolet light after ethidium bromide staining. 
Table 1: Primers used in polymerase chain reaction. 
Primer Sequence Size/bp 
BRCA1-F 5'-GAAGTTGTCATTTTATAAACCTTT-3'  
262 BRCA1-R 5'-TGTCTTTCTTCCCTAGTATGT-3' 
 
2-2 Statistical analysis 
The overall frequency of exon 2 BRCA1mutations were computed for all 30 cases with respect to age at 
diagnosis, family history of breast cancer, and tumor stages. Differences in proportions were evaluated using the 
Z- test for proportions comparing.  
 
3- Results 
In the present study the patients’ age range was 25-70 years and the median is 49 years with high frequency of 
patients in the range of 40-49 years. According to the family history, 29(96.6%) of patients had negative family 
history which statistically high significance differences (p value=0.0151 <0.01) in comparison with patients that 
have positive family history1(3.33%). The distribution of patients according to the tumor stages showed that 
5(16.6%) out of total patients were stage I, 14(46.6%) were stage II, 10(33.33%) were stage III, and 1 (3.33%) 
were stage IV. Relation between BRCA1gene mutations and clinicopathologic parameters, are listed in Table 2. 
The results of the present study showed that, out of the 30 samples with breast cancer and ten samples of  
Healthy controls examined for exon2 of BRCA1gene mutation,9(30%) samples were positive, which was 
significantly higher (p value=0.0984 <0.05) in compare with healthy controls that showed no mutation for 
BRCA1gene and 21(70%) of samples were negative for BRCA1 gene mutation (Fig. 1) . 
In correlation with age groups, the present study showed statistically significant differences in the 
frequency of BRCA1gene mutation with age while no significant differences with family history since all mutant 
samples were negative for family history. In correlation with tumor stage the results of the present study showed 
that the highest percentage of BRCA1gene mutation positive patients 7(77.77%) were stage II that statistically no 
significant differences from percentage of stage III BRCA1gene mutation positive patients 2(22.22%) (p value= 0. 
192),while both stage I and IV showed no mutation. 
 
Figure 1. PCR products analysis for BRCA1 gene mutation in breast cancer samples. L: 100 bp DNA ladder, M: 
mutant tumor sample, C: control, W: wild sample . 
 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.7, No.4, 2017 
 
47 
Table 2. Patient characteristics, type of tumor, stage of tumor, and frequency of mutations 
Total Number Patient  30                                           BRCA1 mutation number 9 of 30 
Characteristics All cases 
(N 30) 
BRCA1 mutation  
( N 9 of 30) 
Age groups   
20-29 1 (3%) 0 
30-39 6(20%) 3(33.33%) 
40-49 15(27.27%) 3(33.33%) 
50-59 9(30%) 1(11.11%) 
60-69 7(23%) 2(22.22%) 
70-79 1(3%) 0 
Family history   
Positive 1(3.33%) 0 
Negative 29(96.6%) 9(100%) 
Tumor stage   
Stage I 5(16.6%) 0 
Stage II 14(46.6%) 7(77.77%) 
Stage III 10(33.33%) 2(22.22%) 
Stage IV 1(3.33%) 0 
 
4-Discussion 
Multiple menstrual and reproductive events; menarche, pregnancy, breast feeding may alter breast cancer risk. 
Studies have also consistently identified an elevated risk of contra lateral breast cancer in BRCA mutation 
carriers.  
In the present study, the frequency of BRCA1 mutation was 30% in the patients. These results have 
some similarity to that reported by Lahad et al. (1997) who found the mutation in 19% of breast cancer patients 
in Ashkenazi Jewish. However our result was higher than 1.2% reported by Peelen et al. (1997), Santarosa et al. 
(1999) who found the mutation in 10% of Italian females with familial breast cancer, and El gezeery et al.(2008) 
who found the mutation in 4(10%) in Egyptian female patients with breast cancer. This variation in the 
frequency may be attributed to the ethnic differences, on the other hand the results were much lower than that of 
Al-mashdani who detected BRCA1 mutations in 30 cases (83.33%) of Iraqi patients(Jumaa , 2013), and lower 
than the frequency of BRCA1 exon 2 mutation which found in 55% (11/20) patients of breast cancer and only 
20% (2/10) healthy control subjects carried this mutation by Mohammad et al.(2014).  The age is an important 
risk factor for breast cancer as the risk increases with age, so occurrence of breast cancer in young age group 
gives strong implication for the presence of inherited genetic predisposition for breast cancer (Lahad et al., 1997). 
In the present study, two patients with BRCA1 mutation were below 40 years (22.22%). Several studies found 
frequencies of 3.5%, 6.7%, 8%, 9% and 20% in the patients below 40 years of age (El gezeery et al., 2008 ; Sue 
Richards et al., 1997 ; Peto et al., 1999). In the present study the other 7 patients carrying the mutation were 
above 40 years (77.77%). Other studies reported frequencies of 1.9% 2% and 13% in patients above 40 years of 
age (El gezeery et al., 2008 ; Peto et al., 1999 ; Abeliovich et al ., 1997). Although the differences between the 
results of many studies conducted in different populations, most of these studies concluded that BRCA1 gene 
mutation is a strong candidate for early onset breast cancer than in late onset breast cancer. This was inconsistent 
with our results as the frequency of the mutation was higher in the old age group. 
A positive family history of breast cancer usually reflects genetic susceptibility and it can be considered 
as one of the strongest risk factors for the disease (Margolin & Lindblom , 2006). In the present study, all the 9 
mutant patients (100%) had negative family history. Our finding is lower than 13.5 % reported by El gezeery et 
al.(2008) 7.4% reported by Friedman et al. (1995) and 5.8% reported by Guranet al. (2005) in patients with 
positive family history. In conclusion, we noticed that the result of present study different from that reported 
previously which indicated that BRCA1 gene mutation account for no more than 5–10% of breast cancer cases in 
compare with our results 30%. These differences may be due to multiple reasons including choosing of random 
samples instead of particular samples with definite family history as followed in other studies, the other reason is 
may be related with environmental factors and geographical disruption of the samples which showed that the 
frequent of this gene mutation in Iraqi patients is differs from that obtained from the previous studies, we also 
noticed that sometimes there is either omission from hospital side or secrecy from patients side in getting or 
providing real information about family history which leading in result to get inaccurate family history. Until 
recently, the management of BRCA mutation-associated breast cancer did not necessarily differ from the 
management of sporadic breast cancer. However, consideration of the future cancer risks faced by this 
population, new data regarding unique sensitivity to systemic therapies and the availability of BRCA mutation 
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testing at the time of breast cancer diagnosis are changing this treatment regimen. 
 
5-Conclusions 
In conclusion, There was a surprising high degree of BRCA1 gene mutation carriage rate, BRCA1 gene mutations 
were found to have a relatively high frequency in tumor stage II  in the study. 
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